Scholar Rock Navigates FDA Hurdle, Secures $550M for SMA Drug Launch

CAMBRIDGE, MA – March 03, 2026 – Scholar Rock is navigating a high-stakes period of anticipation and preparation as it eyes the 2026 launch of its first potential blockbuster drug, apitegromab. While reporting its 2025 financial results, the biopharmaceutical company laid out a strategic path forward that hinges on resolving a critical manufacturing hurdle, a challenge it now faces with a newly secured $550 million financial war chest.

The company's lead candidate for Spinal Muscular Atrophy (SMA), apitegromab, successfully demonstrated significant clinical benefit in its pivotal Phase 3 trial. However, its journey to the U.S. market was abruptly halted in September 2025 by a Complete Response Letter (CRL) from the Food and Drug Administration (FDA). The rejection was not due to the drug itself—the FDA raised no concerns about apitegromab's safety, efficacy, or its core manufacturing—but was instead tied exclusively to issues at a third-party fill-finish facility in Bloomington, Indiana, formerly operated by Catalent.

Now, with the facility under new ownership and a clear remediation plan in motion, Scholar Rock is signaling its readiness to resubmit its application and initiate a commercial launch that could reshape the treatment landscape for a devastating neuromuscular disease.

The Final Hurdle: A Factory in Focus

The fate of apitegromab's U.S. launch currently rests on the successful reinspection of the Bloomington, Indiana manufacturing site, which was acquired by Novo Nordisk in late 2024. The facility had been placed under intense FDA scrutiny following an inspection in mid-2025 that uncovered what the agency deemed “significant violations” of Current Good Manufacturing Practice (cGMP) regulations.

An FDA Warning Letter issued in November 2025 detailed serious deficiencies, including repeated instances of contamination, such as hair found in or near drug product vials, and inadequate investigations into these deviations. These findings led the agency to issue its most severe classification, “Official Action Indicated (OAI),” and ultimately blocked the approval of new products filled at the site, including apitegromab.

However, recent developments suggest a path is clearing. According to Scholar Rock, a meeting between the FDA and the facility's new management in early 2026 was “constructive.” In a significant positive sign, the FDA did not request any additional corrective actions beyond the comprehensive remediation plan already underway by Novo Nordisk.

“Our highest priority is to serve children and adults living with SMA by bringing apitegromab through the regulatory review process as quickly as possible,” stated David L. Hallal, Chairman and CEO of Scholar Rock. “We are encouraged by the FDA’s continued engagement and shared sense of urgency... We are ready to resubmit our apitegromab BLA following successful reinspection of the site by the FDA.”

To mitigate future supply chain risks, Scholar Rock is also advancing technology transfer to a second U.S.-based fill-finish facility, with plans to submit for its approval later in 2026. This dual-sourcing strategy is designed to ensure supply continuity for what the company hopes will be high commercial demand.

A $550 Million War Chest for the Commercial Battle

While navigating the regulatory complexities, Scholar Rock has decisively strengthened its financial foundation. The company announced it has secured a new non-dilutive debt facility for up to $550 million from funds managed by Blue Owl Capital. This strategic financing provides a massive injection of capital without diluting shareholder equity, a strong vote of confidence from a major financial partner.

The deal is structured to fuel the company’s growth, with an initial $200 million available in early 2026, followed by an additional $150 million that unlocks upon FDA approval of apitegromab. The funds are earmarked to support the U.S. commercialization, advance key pipeline programs, and fund a European launch, which is anticipated in the second half of 2026, beginning with Germany, pending a decision from the European Medicines Agency (EMA) expected mid-year.

This financial bolstering comes at a critical time. The company reported a net loss of $377.9 million for the full year 2025 as it ramped up spending on research, development, and pre-commercial activities. With $367.6 million in cash and equivalents at year-end, the new debt facility provides a substantial runway to execute its ambitious launch plans.

Redefining SMA and Expanding Horizons

Apitegromab is poised to enter a market with established, effective treatments from Biogen, Roche, and Novartis. However, it is not a direct competitor. Instead, it offers a novel, complementary mechanism of action. Existing SMA therapies are SMN-enhancers that focus on preserving motor neurons. Apitegromab, a myostatin inhibitor, is the first muscle-targeted therapeutic candidate designed to build muscle mass and strength.

This unique approach could provide a significant additive benefit for patients who, despite treatment with an SMN-enhancer, still experience debilitating muscle weakness. Scholar Rock's commercial team is already educating physicians on the importance of treating the “full motor unit”—both the nerve and the muscle—to maximize patient function.

Furthermore, Scholar Rock is proving its myostatin platform has potential far beyond SMA. The company is on track to initiate a Phase 2 trial, named FORGE, in mid-2026 to evaluate apitegromab for Facioscapulohumeral Muscular Dystrophy (FSHD), a progressive muscle-wasting disease with no approved treatments. Affecting an estimated 30,000 people in the U.S. and Europe, success in FSHD would represent another major breakthrough for patients and a significant expansion of the company's market opportunity.

Alongside the apitegromab programs, the company is advancing SRK-439, a next-generation myostatin inhibitor with potential for subcutaneous administration, with initial data from its Phase 1 study expected in the second half of 2026. With a clear regulatory hurdle to overcome, a fortified balance sheet, and a promising pipeline, Scholar Rock is positioning 2026 to be its most transformative year yet. For patients and investors alike, all eyes are now on the FDA's next move at the Bloomington facility, a decision that will unlock the next chapter for Scholar Rock.